Ce.B.Tec. P.C. is a research-intensive biotechnology company specializing in advanced bioelectric biosensor technologies for rapid, highly sensitive, and cost-effective diagnostics at the point of care. Originating as a spin-off from the Agricultural University of Athens, the company leverages molecular identification through membrane engineering to develop innovative diagnostic platforms with broad applicability across medicine, agri-food, environmental monitoring, and biotechnology. Ce.B.Tec. has received significant recognition for its innovations, including international awards for its ultra-rapid SARS-CoV-2 antigen test and its portable anthrax detection system, underscoring its strong scientific credibility and technological excellence. With more than 25 years of cumulative research experience, a growing portfolio of national and international patents, and active collaborations with academic, industrial, and financial partners, the company combines deep scientific expertise with market-oriented development. Its core activities span consulting, contracted research and development, analytical services, and proprietary innovation, enabling Ce.B.Tec. to deliver tailored diagnostic solutions while continuously expanding its flexible, low-cost diagnostic platforms for global impact.
Oceania (e.g. Australia, New Zealand) East Asia (e.g. China, Japan)South East Asia (e.g. Thailand, Philippines)South Asia (e.g. India)Arabia & Middle East (e.g. Emirates)Africa Subsahara (e.g. Nigeria, South Africa)North AfricaLatin and South America (e.g. Mexico, Chile)North America (USA & Canada)Scandinavia (Nordics)Baltic StatesCentral and Western EuropeSouth and East Europe